Case study

PGHL

Procter & Gamble Health Limited

Worth a closer look1y model +5.3%

Each stock's 10,000-path forecast, rendered as light.

62Score

Procter & Gamble Health Limited (PGHL) Stock Analysis & Case Study

Is PGHL a good buy? The data-driven verdict.

Procter & Gamble Health Limited (PGHL) trades at ₹6,068,on the numbers it worth a closer look, a Downstox Snapshot Score of 62/100.

On the numbers, Procter & Gamble Health Limited (PGHL) worth a closer look, a Downstox Snapshot Score of 62/100, weighing premium at 30.3× earnings, ROE of 61.6%, a 58% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.

Last updated . Data snapshot for research, not investment advice.

PGHL fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield

Market cap
₹10,082 Cr
Current price
₹6,068
P/E ratio
30.3×
P/B ratio
19.20×
Book value
₹316
Dividend yield
2.55%
ROCE
83.5%
ROE
61.6%
Piotroski F-Score
6/8

How PGHL ranks against the 2,373 companies in our screener

Is PGHL overvalued? PGHL P/E vs peers

PGHL trades at 30.3× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.

PGHL share price target 2027, 2028, 2029, 2030, 2031, a probability view

Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of PGHL history (22%/yr drift, 25%/yr volatility).

YearLow (P10)Median target (P50)High (P90)Upside vs today
PGHL 2027₹4,679₹6,472₹8,951+5%
PGHL 2028₹4,292₹6,817₹10,828+11%
PGHL 2029₹4,077₹7,180₹12,644+17%
PGHL 2030₹3,944₹7,563₹14,501+23%
PGHL 2031₹3,818₹7,966₹16,620+30%

Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.

What is the probability PGHL goes up, or doubles?

58%
Higher in 1 year
Modelled chance the price is above today in 12 months
67%
Higher in 5 years
Modelled chance the price is above today in 5 years
23%
Doubles in 5 years
Modelled chance of reaching ₹12,289 within 5 years

The bull case for PGHL

  • PGHL's return on equity of 61.6% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
  • PGHL's return on capital employed of 83.5% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
  • PGHL's dividend yield of 2.5% ranks in the 91st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
  • Upside scenario: the model's optimistic (P90) 3-year path reaches ₹12,644.

The bear case & risks

  • PGHL's P/E of 30.6x is lower than 45% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
  • A steep 19.2× price-to-book means most of the value is intangible/expectations, not assets on the books.
  • Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹4,077.

PGHL volatility & expected range, how bumpy is the ride?

Over the last 9.8 years PGHL compounded at 22%/year with annualized volatility of 25%. That volatility implies a 1-year 80% range of ₹4,679-₹8,951, the honest backbone behind any single price target.

PGHL price forecast, the full 60-month probability fan

Spot Price · Today
₹0
Based on 9.8 years of daily NSE data ·0.0% annualised volatility
5-yr median forecast
₹0
P(price ↑ in 5y)
0%
1-Year Forecast
2027
₹0
Median (P50)
5.3%
80% range₹4,679-₹8,951
P(price ↑)58%
P(price 2×)1%
3-Year Forecast
2029
₹0
Median (P50)
16.9%
80% range₹4,077-₹12,644
P(price ↑)64%
P(price 2×)11%
5-Year Forecast
2031
₹0
Median (P50)
29.6%
80% range₹3,818-₹16,620
P(price ↑)67%
P(price 2×)23%

PGHL price probability fan

Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.

Probability Fan
PGHL simulated paths · 60 months · 10,000 trials
P10-P90 (80%)P25-P75 (50%)Median (P50)

Probability of key outcomes

What are the odds PGHL hits common targets within the simulated horizon?

0%
P(↑ 1Y)
Above today's price in 1 year
0%
P(↑ 5Y)
Above today's price in 5 years
0%
P(2×)
Doubles within 5 years
0%
P(↓)
Falls below today in 5 years

Full multi-horizon detail on the PGHL price target & forecast page.

PGHL Piotroski F-Score: 6/8, how financially strong is it?

6/8

The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. PGHL scores 6/8, mixed financial health.

PGHL MTF margin & leverage across 11 brokers

Margin Trading Facility lets you buy PGHL with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):

BrokerMargin requiredApprox. leverage
Upstox35.00%2.9×
Zerodha27.52%3.6×
Groww27.53%3.6×
Dhan27.52%3.6×
Kotak Neo30.03%3.3×
Paytm Money27.53%3.6×
Pocketful27.35%3.7×
Fyers27.78%3.6×
Anand Rathi27.52%3.6×
Bajaj Broking28.00%3.6×
Share IndiaCHEAPEST27.18%3.7×

Compare every broker on the PGHL MTF page.

About Procter & Gamble Health Limited: sector, index & market-cap context

Procter & Gamble Health Limited (PGHL) is a small-cap NSE-listed company, with a market capitalisation of ₹10,082 Cr. See more stocks on our screener.

How the PGHL Snapshot Score & forecast are built

The Downstox Snapshot Score is a transparent, rules-based read of Procter & Gamble Health Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.

This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.

PGHL analysis, FAQs

Is Procter & Gamble Health Limited (PGHL) a good buy?

On the numbers, Procter & Gamble Health Limited (PGHL) worth a closer look, a Downstox Snapshot Score of 62/100, weighing premium at 30.3× earnings, ROE of 61.6%, a 58% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.

Is PGHL overvalued or undervalued?

PGHL trades at 30.3× earnings, premium versus the ~22× long-run Nifty average.

What is the PGHL share price target for 2031?

PGHL's probability-weighted 2031 median target is ₹7,966, with an 80% range of ₹3,818-₹16,620 (10,000-path Monte-Carlo).

What is the probability PGHL doubles in 5 years?

The modelled probability of PGHL reaching ₹12,289 (2×) within 5 years is 23%.

What is the bull case for PGHL?

PGHL's return on equity of 61.6% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. PGHL's return on capital employed of 83.5% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. PGHL's dividend yield of 2.5% ranks in the 91st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.

What are the risks in PGHL?

PGHL's P/E of 30.6x is lower than 45% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 19.2× price-to-book means most of the value is intangible/expectations, not assets on the books.

More on PGHL